- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Case Reports in Medicine
Volume 2012 (2012), Article ID 836893, 7 pages
Severe Pulmonary Hypertension Caused by Smoldering Plasma Cell Myeloma: An Autopsy Case of POEMS Syndrome
1Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Tokyo, Mitaka 181-8611, Japan
2Department of Pathology, Nerima General Hospital, 1-24-1 Asahigaoka, Tokyo, Nerima 176-8530, Japan
Received 9 August 2012; Revised 7 November 2012; Accepted 8 November 2012
Academic Editor: Raed Dweik
Copyright © 2012 Katsuya Chinen and Yasunori Fujioka. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. S. Allam, C. C. Kennedy, T. R. Aksamit, and A. Dispenzieri, “Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients,” Chest, vol. 133, no. 4, pp. 969–974, 2008.
- A. Dispenzieri, R. A. Kyle, M. Q. Lacy et al., “POEMS syndrome: definitions and long-term outcome,” Blood, vol. 101, no. 7, pp. 2496–2506, 2003.
- J. Li, D. B. Zhou, Z. Huang et al., “Clinical characteristics and long-term outcome of patients with POEMS syndrome in China,” Annals of Hematology, vol. 90, no. 7, pp. 819–826, 2011.
- T. Nakanishi, I. Sobue, Y. Toyokura, et al., “The Crow-Fukase syndrome: a study of 102 cases in Japan,” Neurology, vol. 34, no. 6, pp. 712–720, 1984.
- M. J. Soubrier, J. J. Dubost, and B. J. M. Sauvezie, “POEMS syndrome: a study of 25 cases and a review of the literature,” The American Journal of Medicine, vol. 97, no. 6, pp. 543–553, 1994.
- K. Takatsuki and I. Sanada, “Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases,” Japanese Journal of Clinical Oncology, vol. 13, no. 3, pp. 543–556, 1983.
- R. K. Gherardi, L. Bélec, M. Soubrier et al., “Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome,” Blood, vol. 87, no. 4, pp. 1458–1465, 1996.
- P. Lesprit, B. Godeau, F. J. Authier et al., “Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 3, pp. 907–911, 1998.
- T. Araki, T. Konno, R. Soma et al., “Crow-Fukase syndrome associated with high-output heart failure,” Internal Medicine, vol. 41, no. 8, pp. 638–641, 2002.
- L. Feinberg, D. Temple, E. De Marchena, R. Patarca, and A. Mitrani, “Soluble immune mediators in POEMS syndrome with pulmonary hypertension: case report and review of the literature,” Critical Reviews in Oncogenesis, vol. 10, no. 4, pp. 293–302, 1999.
- H. Niimi, K. Arimura, M. Jonosono et al., “VEGF is causative for pulmonary hypertension in a patient with Crow-Fukase (POEMS) syndrome,” Internal Medicine, vol. 39, no. 12, pp. 1101–1104, 2000.
- S. Rached, R. A. Athanazio, S. A. Dias Jr., C. Jardim, and R. Souza, “Systemic corticosteroids as first-line treatment in pulmonary hypertension associated with POEMS syndrome,” Jornal Brasileiro de Pneumologia, vol. 35, no. 8, pp. 804–808, 2009.
- D. S. Helmersen, G. T. Ford, S. M. Viner, and W. R. Auger, “POEMS syndrome: a clue to understanding primary pulmonary hypertension? A review of current insights into the pathogenesis of primary pulmonary hypertension,” The Canadian Journal of Cardiology, vol. 16, no. 8, pp. 975–981, 2000.
- E. Stacher, B. B. Graham, J. M. Hunt, et al., “Modern age pathology of pulmonary arterial hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 3, pp. 261–272, 2012.
- M. Hara, I. Mizote, Y. Nakaoka et al., “A case of non-cardiogenic acute pulmonary edema in a patient with POEMS syndrome-associated pulmonary arterial hypertension,” Annals of Hematology, vol. 90, no. 4, pp. 489–490, 2011.
- H. Iwasaki, K. Ogawa, H. Yoshida et al., “Crow-Fukase syndrome associated with pulmonary hypertension,” Internal Medicine, vol. 32, no. 7, pp. 556–560, 1993.
- P. Jouve, M. Humbert, M. P. Chauveheid, X. Jaïs, and T. Papo, “POEMS syndrome-related pulmonary hypertension is steroid-responsive,” Respiratory Medicine, vol. 101, no. 2, pp. 353–355, 2007.
- J. Lewerenz, A. Gocht, P. H. Hoeger et al., “Multiple vascular abnormalities and a paradoxical combination of vitamin B12 deficiency and thrombocytosis in a case with POEMS syndrome,” Journal of Neurology, vol. 250, no. 12, pp. 1488–1491, 2003.
- D. Mukerjee, E. Kingdon, M. Vanderpump, and J. G. Coghlan, “Pathophysiological insights from a case of reversible pulmonary arterial hypertension,” Journal of the Royal Society of Medicine, vol. 96, no. 8, pp. 403–404, 2003.
- H. Okura, I. Gohma, K. Haita, and T. Imanaka, “Thiamine deficiency and pulmonary hypertension in Crow-Fukase syndrome,” Internal Medicine, vol. 34, no. 7, pp. 674–675, 1995.
- S. Ribadeau-Dumas, I. Tillie-Leblond, C. Rose et al., “Pulmonary hypertension associated with POEMS syndrome,” The European Respiratory Journal, vol. 9, no. 8, pp. 1760–1762, 1996.
- C. Rose, M. Zandecki, M. C. Copin et al., “POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells,” Leukemia, vol. 11, no. 8, pp. 1318–1323, 1997.
- M. Sinisalo, A. Hietaharju, J. Sauranen, and O. Wirta, “Thalidomide in POEMS Syndrome: case report,” American Journal of Hematology, vol. 76, no. 1, pp. 66–68, 2004.
- J. P. Viard, P. Lesavre, C. Boitard et al., “POEMS syndrome presenting as systemic sclerosis. Clinical and pathologic study of a case with microangiopathic glomerular lesions,” The American Journal of Medicine, vol. 84, no. 3, pp. 524–528, 1988.
- G. Paciocco, E. Bossone, H. Erba, and M. Rubenfire, “Reversible pulmonary hypertension in POEMS syndrome—another etiology of triggered pulmonary vasculopathy?” The Canadian Journal of Cardiology, vol. 16, no. 8, pp. 1007–1012, 2000.
- S. T. Shiue and D. P. McNally, “Pulmonary hypertension from prominent vascular involvement in diffuse amyloidosis,” Archives of Internal Medicine, vol. 148, no. 3, pp. 687–689, 1988.
- Y. Hattori, M. Shimoda, S. Okamoto, T. Satoh, T. Kakimoto, and Y. Ikeda, “Pulmonary hypertension and thalidomide therapy in multiple myeloma,” British Journal of Haematology, vol. 128, no. 6, pp. 885–887, 2005.
- J. Lehtonen and P. Kettunen, “Pulmonary hypertension as a dominant clinical picture in a case of amyloidosis and smoldering multiple myeloma,” International Journal of Cardiology, vol. 115, no. 1, pp. E29–E30, 2007.
- S. Yaqub, K. G. Moder, and M. Q. Lacy, “Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis,” Mayo Clinic Proceedings, vol. 79, no. 5, pp. 687–689, 2004.
- M. Humbert, O. Sitbon, A. Chaouat et al., “Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era,” Circulation, vol. 122, no. 2, pp. 156–163, 2010.
- J. Li, W. Zhang, L. Jiao et al., “Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome,” Blood, vol. 117, no. 24, pp. 6445–6449, 2011.
- C. Rostagno and S. Ciolli, “Transient severe symptomatic pulmonary hypertension as onset symptom in multiple myeloma,” Annals of Hematology, vol. 85, no. 9, pp. 627–628, 2006.